Payment overview · 2025
General Payments
$128,259.42
199 reported records · 24 companies
Healthcare provider profile · identity verified
Mark Warren, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · GREENVILLE, NC · NPI 1629073010
Verified facts
What the public records show
CMS Open Payments records show Mark Warren, M.D. received $128,259.42 in general payments during 2025 across 199 reported records.
Ascendis Pharma Endocrinology Inc accounted for 68.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Kerendia, Korlym, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 821 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $87,206.23 | 68.0% | 93 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25,320.85 | 19.7% | 42 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $8,135.05 | 6.3% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $5,466.90 | 4.3% | 8 | 2025 |
| Senseonics, Incorporated | Unresolved — no canonical attribution shown | $800.00 | 0.6% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $189.74 | 0.1% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $186.00 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.24 | 0.1% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.00 | 0.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $103.03 | 0.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $79.88 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $68.32 | 0.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $61.42 | 0.1% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $57.88 | 0.1% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $45.40 | 0.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.97 | 0.0% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $37.62 | 0.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $34.94 | 0.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.75 | 0.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $32.71 | 0.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $21.81 | 0.0% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $20.82 | 0.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.32 | 0.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.54 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,591.00 | 44 |
| Travel and Lodging | $11,392.89 | 65 |
| Consulting Fee | $6,000.00 | 1 |
| Food and Beverage | $4,535.56 | 86 |
| Compensation for serving as faculty or as a speaker for a medical education program | $700.00 | 1 |
| Education | $39.97 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $87,206.23 | 93 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12,739.24 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $12,556.75 | 21 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $8,115.84 | 13 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $4,764.54 | 7 | 2025 |
Source payment records
|
|||||
| Eversense Normalized: eversense |
Device | Senseonics, Incorporated | $800.00 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $189.74 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $189.74 | 3 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $189.74 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $186.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.55 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $109.00 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $103.03 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $79.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $68.32 | 3 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $61.42 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $57.88 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $45.40 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $45.40 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $45.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.40 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $37.62 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $24.86 | 3 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $19.21 | 6 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 821 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 84 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 260 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
260 | 52 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
235 | 35 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
821 | 135 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 821 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 175 |
| Metformin Hcl Er | Metformin Hcl | 335 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 90 |
| Tresiba Flextouch U-200 | Insulin Degludec | 261 | 49 |
| Synthroid | Levothyroxine Sodium | 260 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 53 |
| Tresiba Flextouch U-100 | Insulin Degludec | 237 | 60 |
| Trulicity | Dulaglutide | 235 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 66 |
| Glimepiride | Glimepiride | 228 | 65 |
| Jardiance | Empagliflozin | 226 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 209 | 57 |
| Metformin Hcl | Metformin Hcl | 183 | 46 |
| Simvastatin | Simvastatin | 178 | 46 |
| Gabapentin | Gabapentin | 175 | 41 |
| Farxiga | Dapagliflozin Propanediol | 172 | 28 |
| Novolog Flexpen | Insulin Aspart | 160 | 42 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 159 | 57 |
| Humalog Kwikpen U-100 | Insulin Lispro | 149 | 34 |
| Repatha Sureclick | Evolocumab | 146 | 25 |
| Losartan Potassium | Losartan Potassium | 142 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 41 |
| Novolog | Insulin Aspart | 130 | 34 |
| Ezetimibe | Ezetimibe | 127 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 37 |
| Furosemide | Furosemide | 125 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 33 |
| Humalog | Insulin Lispro | 115 | 32 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 113 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 18 |
| Mounjaro | Tirzepatide | 94 | 22 |
| Omeprazole | Omeprazole | 92 | 23 |
| Rybelsus | Semaglutide | 84 | 16 |
| Pregabalin | Pregabalin | 83 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 82 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 24 |
| Lisinopril | Lisinopril | 76 | 24 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 74 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 73 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 72 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 69 | 23 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 68 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 11 |
| Atenolol | Atenolol | 64 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 14 |
| Januvia | Sitagliptin Phosphate | 60 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 56 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 55 | suppressed |
| Calcitriol | Calcitriol | 54 | 11 |
| Insulin Lispro | Insulin Lispro | 54 | 11 |
| Invokana | Canagliflozin | 54 | 11 |
| Fluconazole | Fluconazole | 53 | 20 |
| Testosterone | Testosterone | 53 | 17 |
| Armour Thyroid | Thyroid,pork | 52 | 12 |
| Lyumjev | Insulin Lispro-Aabc | 51 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 50 | 15 |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 49 | 12 |
| Alprazolam | Alprazolam | 48 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Vascepa | Icosapent Ethyl | 46 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 44 | 14 |
| Methimazole | Methimazole | 44 | suppressed |
| Victoza 3-Pak | Liraglutide | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 11 |
| Estradiol | Estradiol | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 13 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 18 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 34 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Insulin Aspart | Insulin Aspart | 31 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Levemir | Insulin Detemir | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Afrezza | Insulin Regular, Human | 23 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Novofine 32 | Pen Needle, Diabetic | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Gvoke Hypopen 2-Pack | Glucagon | 20 | 17 |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Korlym | Mifepristone | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Repatha Pushtronex | Evolocumab | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Cabergoline | Cabergoline | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Omnitrope | Somatropin | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128,259.42 · 199 records | Ascendis Pharma Endocrinology Inc | AFREZZA, CRENESSITY, CeQur Simplicity, EVENITY, EVKEEZA, Eversense, FREESTYLE LIBRE 2, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, JATENZO, Kerendia, Korlym, MOUNJARO, NP Thyroid 60, Ozempic, QUTENZA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, SYNTHROID, TEPEZZA, TWIIST, TZIELD, UBRELVY, UNITHROID, Wegovy, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error